Prostate Cancer - Results from #40

Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT). May 30, 2023

Trends in prostate cancer incidence among Black men in the Caribbean and the United States. May 30, 2023

Identification of incidental brain tumors in prostate cancer patients via PSMA PET/CT. May 30, 2023

Experience with the US health care system for Black and White patients with advanced prostate cancer. May 30, 2023

Waldenström macroglobulinemia with secondary pure red cell aplasia in a patient with metastatic castrate resistant prostate cancer receiving an immune checkpoint inhibitor: a case report. May 29, 2023

ACR Appropriateness Criteria® Pretreatment Detection, Surveillance, and Staging of Prostate Cancer: 2022 Update. May 29, 2023

Preclinical Evaluation of a PSMA-Targeting Homodimer with an Optimized Linker for Imaging of Prostate Cancer. May 29, 2023

Impact of Magnetic Resonance Imaging Targeting on Pathologic Upgrading and Downgrading at Prostatectomy: A Systematic Review and Meta-analysis. May 29, 2023

Association between RCT methodology and disease indication with mineralocorticoid-related toxicity for patients receiving abiraterone acetate for advanced prostate cancer: A meta-analysis of RCTs. May 29, 2023

Multi-Gene Next-Generation Sequencing Panel for Analysis of BRCA1/BRCA2 and Homologous Recombination Repair Genes Alterations Metastatic Castration-Resistant Prostate Cancer. May 29, 2023

The long-term incidence and quality of life outcomes associated with treatment-related toxicities of external beam radiotherapy for prostate cancer. May 29, 2023

ACR Appropriateness Criteria® Post-Treatment Follow-up of Prostate Cancer: 2022 Update. May 29, 2023

The Immunogenomic Landscape of Neuroendocrine Prostate Cancer. May 26, 2023

A synthetic lethal screen for Snail-induced enzalutamide resistance identifies JAK/STAT signaling as a therapeutic vulnerability in prostate cancer. May 26, 2023

Hypofractionated, Dose Escalation Radiotherapy for High-Risk Prostate Cancer: the safety analysis of the Prostate Cancer Study-5 (PCS-5), a GROUQ led phase III trial. May 26, 2023

Treatment of Advanced Metastatic Prostate Cancer Using Molecular-Targeted Therapy: Radioligand Lutetium-177 Prostate-Specific Membrane Antigen. May 26, 2023

Insurer coverage of prostate cancer biomarkers. May 26, 2023

Darolutamide in Spanish patients with nonmetastatic castration-resistant prostate cancer: ARAMIS subgroup analysis. May 25, 2023

The Streaming Web-Based Exercise at Home Study for Breast and Prostate Cancer Survivors: A Feasibility Study Protocol. May 25, 2023

Re-sensitization to pembrolizumab following PSMA-CD3 T-cell redirection therapy with JNJ-081 in a patient with mismatch repair-deficient metastatic castration-resistant prostate cancer: a case report. May 25, 2023

Page 3 of 1305